Curriculum vitae veritti

Name: Daniele VerittiBirth date: 29 Dec 1981Birth place: Gemona del Friuli (Udine), ItalyCitizenship: ItalianMarital status: married Home address: Via Aquileia 14, 33013 Gemona del Friuli (Udine), Italy.
Telephone: +39.0432972727Cell phone: +39.3408014456E-mail addressSkype: verittidaniele Attending physicianDepartment of Ophthalmology, University of Udine, Udine, Italy EUROPEAN SCHOOL FOR ADVANCED STUDIES IN OPHTHALMOLOGYRetinal Diseases Module Department of Ophthalmology, University of Udine, Udine, Italy Thesis: “Triple Therapy for Anti-VEGF Non-responders in Neovascular Age-Related Macular Degeneration. Ranibizumab, Juxtascleral Triamcinolone Acetonide and Photodynamic therapy with verteporfin”. Maximum grades and honours.
M.D. DEGREEUniversity of Udine, Udine, Italy Dissertation title: “Posterior Juxtascleral Infusion of Modified Triamcinolone Acetonide Formulation For Refractory Diabetic Macular Edema. One-year Follow Up” INTERNSHIP IN OPHTHALMOLOGYDepartment of Ophthalmology, University of Udine, Udine, Italy HIGH SCHOOL DEGREELiceo scientifico “Luigi Magrini”, Gemona del Friuli (Udine), Italy Thesis title: “Gravitational Lenses: Mirages in the Cosmos” Lanzetta P, Monaco P, Veritti D. In reply to: Metha S. Major ocular complications after organ
transplantation. Indian J Ophthalmol. 2004; 52:255-6.
Lanzetta P, Polito A, Veritti D. Subthreshold laser. Ophthalmology. 2008; 115:216-216e1.
Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisible Micropulse Diode Laser (810
nm) Treatment of Central Serous Chorioretinopathy. A Pilot Study. Eur J Ophthalmol. 2008;
18:934-40.
Veritti D, Lanzetta P, Perissin L, Bandello F. Posterior Juxtascleral Infusion of Modified Triamcino-
lone Acetonide Formulation for Refractory Diabetic Macular Edema. One-Year Follow Up. Invest
Opthalmol vis Sci. 2009; 50:2391-7.
Veritti D, Lanzetta P, Bandello F, Gortana Chiodini R. Viscoelastic Agent Retention and Failed
Macular Hole Surgery. Retinal cases & brief reports. 2009; 3:77-9.
Bandello F, Battaglia Parodi M, Lanzetta P, Loewenstein A, Massin P, Menchini F, Veritti D. Diabe-
tic Macular Edema. Dev Ophthalmol. 2010; 47:73-110.
Veritti D, Sarao V, Lanzetta P. Update on Combination Therapy in Wet Age-related Macular De-
generation. Exp Rev Ophthalmol. 2010;5:681-688.
VIA AQUILEIA 14 33013 GEMONA DEL FRIULI (UDINE) ITALY Veritti D, Perissin L, Zorzet S, Lanzetta P. The Effect of Triamcinolone Acetonide, Sodium Hyalu-
ronate, and Chondroitin Sulfate on Human Endothelial Cells: an in Vitro Study. Eur J Ophthalmol.
2010; S6:75-9.
Sheth S, Lanzetta P, Veritti D, Zucchiatti I, Savorgnani C, Bandello F. Experience with the Pascal®
photocoagulator: an analysis of over 1,200 laser procedures with regard to parameter refinement.
Indian J Ophthalmol. 2011 Mar-Apr;59(2):87-91.
Veritti D, Vergallo S, Lanzetta P. Triple therapy for corneal neovascularization: a case report. Eur J
Ophthalmol. 2011; in press.
Veritti D, Toneatto G, Lanzetta P. Low-concentration infracyanine green-assisted internal limiting
membrane peeling in idiopathic macular pucker 25-gouge surgery. Eur J Ophthalmol. 2011; in press.
Veritti D, Di Giulio A, Sarao V, Lanzetta P. Drug safety evaluation of intravitreal triamcinolone
acetonide. Expert Opin Drug Saf. 2012; 11:331-40.
Veritti D, Sarao V, Lanzetta P. Online optical coherence tomography during subthreshold laser
irradiation. Eur J Ophthalmol. 2011; in press.
Sarao V, Veritti D, Lanzetta P. Triamcinolone acetonide for the treatment of diabetic macular ede-
ma. Europ Ophthalmic Rev. 2011; in press.
Veritti D, Sarao V, Lanzetta P. Choroidal neovascularization. Ophthalmologica. 2012; 227:11-20.
Antonutto G, Veritti D, Lanzetta P, Melato M. Occhio. In: Mariuzzi GM, ed. Anatomia Patologica
e Correlazioni Anatomo-Cliniche. 1st ed. Padova, Italy: Piccin; 2006; vol 2: 2489-521.
Veritti D, Lanzetta P. Ocular complications after hand transplantation. In: Lanzetta M, Dubernard
JM, eds. Hand Transplantation. 1st ed. Milan, Italy: Springer; 2006:241-6.
Polito A, Veritti D, Lanzetta P. Non-proliferative diabetic retinopathy. In: Agarwal A, ed. Fundus
Fluorescein and Indocyanine Green Angiography: A Textbook and Atlas. 1st ed. Thorofare, NJ:
Slack Inc; 2008; chapter 24; 201-6.
Veritti D. Terapia combinata con ranibizumab e verteporfina. In: Lanzetta P, ed. Terapia anti-an-
giogenica in oftalmologia - casi clinici. Torino, Italy: Elleboro sas; 2009; chapter 7; 33-40.
Veritti D, Sborgia C, Boscia F, Smaldone G, Lanzetta P. Trauma and emergencies. In: Agarwal A,
ed. Color atlas of ophthalmology. New York: Thieme; 2009; chapter 1; 1-32.
Bandello F, Battaglia Parodi M, Lanzetta P, Loewenstein A, Massin P, Menchini F, Veritti D. Diabe-
tic Macular Edema. In: Coscas G, ed. Macular edema. A practical approach. Basel: Karger; 2010;
73-110.
Lanzetta P, Veritti D, Dal Mas G, Sarao V. Macular pucker. In: Saxena S, Meyer CH, Ohji M,
Akduman L, eds. Vitreoretinal Surgery. Daryaganj: Jaypee Brothers; 257-75.
Pignatto S, Veritti D, Gabai A, Lanzetta P. Selective laser trabeculoplasty. In: Gunvant P, ed. Glau-
coma - Current Clinical and Research Aspects. Rijeka: In Tech; 2011; 257-72.
Veritti D, Lanzetta P. La degenerazione maculare legata all’età. Scheda allegata a Sole 24 Ore
Sanità, Dicembre 2006, 50.
Veritti D, Lanzetta P. La degenerazione maculare legata all’età. Scheda allegata a Sole 24 Ore
Sanità, Febbraio 2007, 6.
Veritti D, Lanzetta P, Genovese U. La degenerazione maculare legata all’età. Utilizzo off-label dei
farmaci: aspetti generali e risvolti per la terapia dell’AMD (prima parte). Scheda allegata a Sole 24
Ore Sanità, Aprile 2007, 14.
Veritti D, Lanzetta P, Genovese U. La degenerazione maculare legata all’età. Utilizzo off-label dei
farmaci: aspetti generali e risvolti per la terapia dell’AMD (seconda parte). Scheda allegata a Sole 24
Ore Sanità, Maggio 2007, 19.
Veritti D, Lanzetta P. La degenerazione maculare legata all’età. Il trattamento dell’AMD: terapia
fotodinamica con verteporfina e terapie combinate. Scheda allegata a Sole 24 Ore Sanità, Giugno
2007, 28.
Veritti D, Lanzetta P. La degenerazione maculare legata all’età. Ranibizumab e degenerazione
maculare legata all’età. Scheda allegata a Sole 24 Ore Sanità, Settembre 2007, 36.
Lanzetta P, Veritti D, Dal Mas G. Nuove Tecniche di Fotocoagulazione Laser. Occhio alla Retina.
2010;2.
Veritti D, Dal Mas G, Lanzetta P. Triamcinolone acetonide in soluzione viscoelastica per via juxta-
sclerale nel trattamento dell'edema maculare diabetico refrattario. Viscochirurgia.2010:3;36-44.
Veritti D, Sarao V. Stem cells may be the next frontier for retinal disease. Ocular Surgery News
Europe Edition. June 2011.
Veritti D, Gabai A. Development of eye played key role in evolutionary advantage. Ocular Surgery
News Europe Edition. August 2011.
Veritti D, Macor S. Microaneurysms key in detecting diabetic retinopathy. Ocular Surgery News
Europe Edition. September 2011.
Veritti D, Sarao V. Metods aim to decrease laser damage in treatment of retinal, choroidal condi-
tions. Ocular Surgery News Europe Edition. October 2011.
Veritti D, Gabai A. Updated guidelines on use of anti-VEGF alter treatment course for exudative
AMD. Ocular Surgery News Europe Edition. December 2011.
Veritti D, Macor S. Study into pathology, treatment of epimacular membrane continues. Ocular
Surgery News Europe Edition. January 2012.
Veritti D, Toneatto G. Dyes play vital role in vitreoretinal surgery. Ocular Surgery News Europe
Edition. March 2012.
Gabai A, Veritti D. SLT may be a good first-choice treatment for glaucomatous eyes. Ocular Surge-
ry News Europe Edition. May 2012.
TEACHING ASSISTANTMedical Biotechnology, Faculty of Medicine and Surgery. University of Udine, Italy. Taught: Gene Therapy and the Eye, Artificial Vision: Progress and Prospects.
Contact hours: 3. Twenty graduate studentes.
School of Nursing, Faculty of Medicine and Surgery. University of Udine, Italy. Taught: Cataract, Glaucoma, Postoperative Assistance in Ophthalmic Departments.
Contact hours: 4. Forty graduate students.
Medical Biotechnology, Faculty of Medicine and Surgery. University of Udine, Italy. Taught: Gene Therapy and the Eye, Artificial Vision: Progress and Prospects, Corneal and Contact hours: 4. Fifteen graduate students.
Medical School, Faculty of Medicine and Surgery. University of Udine, Italy. Contact hours: 4. Eighty graduate students.
Lanzetta P, Polito A, Roman Pognuz D, Veritti D. Detection of threshold and sub-threshold laser
irradiation with optical coherence tomography. Invest Ophthalmol Vis Sci 2006 47: E-Abstract 5721.
Lanzetta P, Veritti D. Patient management in the era of anti-VEGF theraphy. Presented at the
Korean Retina Society meeting; November 30, 2007; Chungju, Korea.
Veritti D, Lanzetta P, Bandello F. Esperienza preliminare con il laser semiautomatico Pascal. Presen-
ted at the Annual Meeting of the “Società Italiana Laser in Oftalmologia”; January 25, 2008; Cortina
d’Ampezzo, Italy.
Lanzetta P, Veritti D. Anti-VEGF multicentre trials: what have we learned?. Presented at the inter-
national symposium “Macula: Advances in diagnostic and Therapies”; February 8, 2008; Turin, Italy.
Lanzetta P, Veritti D. Anti-VEGF intravitreal injection: when and how?. Presented at the “27e Con-
grés de la Société Tunisienne d’Ophthalmologie”; March 7, 2008; Gammarth, Tunisia.
Lanzetta P, Veritti D. Il futuro della terapia della DMLE. Presented at “Retina 2008: Le degenera-
zioni maculari”; March 8, 2008; Rome, Italy.
Veritti D, Lanzetta P. Retinopatia diabetica, nuove terapie. Presented at “Retina 2008: Le degenera-
zioni maculari”; March 8, 2008; Rome, Italy.
Lanzetta P, Veritti D. Triple Therapy for Choroidal Neovascularization Due to Age-related Macu-
lar Degeneration. Ranibizumab, Iuxtascleral Triamcinolone Acetonide, and Verteporfin PDT. Early
Vascular Changes. Presented at the Macula Society Annual Meeting; March 28, 2008; Palm Beach,
FL, USA.
Veritti D, Lanzetta P, Bandello F. Posterior Juxtascleral Infusion of Modified Triamcinolone Aceto-
nide Formulation for Refractory Diabetic Macular Edema. One-Year Follow Up Invest. Ophthalmol.
Vis. Sci. 2008 49: E-Abstract 3489.
Veritti D, Lanzetta P. Advances in Laser Photocoagulation. Presented at the course “Terapia Laser
Classica della Retina”; May 17, 2008; Rome, Italy.
Lanzetta P, Veritti D. Off-label Avastin use: State of Experience. Presented at the Euretina Con-
gress; May 23, 2008; Vienna, Austria.
Veritti D, Lanzetta P, Bandello F. Infusione juxtasclerale posteriore di triamcinolone acetonide in
nuova formulazione nel trattamento dell’edema maculare diabetico refrattario: 12 mesi di follow-up.
Presented at the Annual Meeting of the “Società Oftalmologica Triveneta”; June 13, 2008; Trieste,
Italy.
Veritti D, Lanzetta P. Juxtascleral Infusion of Triamcinolone Acetonide: a Clinical Case. Presented
at the course: “Retinopatia Diabetica: dalla Diagnosi alla Terapia”; June 23, 2008; Bassano del
Grappa, Italy.
Lanzetta P, Veritti D. Gli steroidi nel trattamento dell’edema maculare diabetico. Presented at the
congress: “La macula diabetica, X edizione Giornate di Chirurgia Vitreoretinica”; October 11, 2008;
Monza, Italy.
Veritti D, Lanzetta P, Bandello F. Studio VITAL: Verteporfin, Triamcinolone Acetonide Iuxtasclera-
le e Lucentis nella degenerazione maculare senile essudativa. Presented at the Annual Meeting of the
“Società Italiana Laser in Oftalmologia”; January 30, 2009; Cortina d’Ampezzo, Italy.
Lanzetta P, Veritti D. Rôle de l’angiographie dans le diagnostic de l’œdème maculaire. Presented at
the 28th Congress of the “Société tunisienne d'ophtalmologie”; March 13, 2009; Tunis, Tunisia.
Lanzetta P, Veritti D. Steroids and diabetic macular edema. Presented at the 28th Congress of the
“Société tunisienne d'ophtalmologie”; March 13, 2009; Tunis, Tunisia.
Lanzetta P, Veritti D. New trends in Laser applications for retinal diseases. Presented at the 28th
Congress of the “Société tunisienne d'ophtalmologie”; March 14, 2009; Tunis, Tunisia.
Veritti D, Lanzetta P. Guida ragionata all’uso degli antiangiogenici. Presented at the congress Retina
2009; March 28, 2009; Rome, Italy.
Zucchiatti I, Veritti D, Lanzetta P, Bandello F. Efficacy and Safety of Pascal Photocoagulator in the
Treatment of Proliferative Diabetic Retinopathy. Presented at the Association for Research in Vision
and Ophthalmology (ARVO) Annual Meeting; May 3, 2009; Fort Lauderdale, FL, USA.
Lanzetta P, Veritti D, Zucchiatti I, Savorgnani C, Drigo D, Bandello F. PASCAL Retinal Photocoa-
gulation: Review of Parameters Applied in 1,242 Treatments. Presented at the Association for Re-
search in Vision and Ophthalmology (ARVO) Annual Meeting; May 3, 2009; Fort Lauderdale, FL, USA.
Veritti D, Lanzetta P, Cascavilla ML, Drigo D, Bandello F. Triple Therapy for Choroidal Neovascu-
larization Due to Age-Related Macular Degeneration. Ranibizumab, Modified Juxtascleral Triamci-
nolone Acetonide, and Verteporfin PDT. Presented at the Association for Research in Vision and
Ophthalmology (ARVO) Annual Meeting; May 4, 2009; Fort Lauderdale, FL, USA.
Menchini F, Battaglia Parodi M, Polini G, Veritti D, Bandello F. Intravitreal Ranibizumab for Reti-
nal Angiomatous Proliferation. Presented at the Association for Research in Vision and Ophthalmo-
logy (ARVO) Annual Meeting; May 4, 2009; Fort Lauderdale, FL, USA.
Lanzetta P, Veritti D. Drug Delivery. Presented at the congress Retina in Progress: Present and Futu-
re; June 4-6, 2009; Milan, Italy.
Lanzetta P, Veritti D. Macular Edema in Diabetic Retinopathy. Presented at the congress Retina in
Progress: Present and Future; June 4-6, 2009; Milan, Italy.
Lanzetta P, Veritti D. Steroids in Diabetic Macular Edema. Presented at the congress Retina in
Progress: Present and Future; June 4-6, 2009; Milan, Italy.
Lanzetta P, Veritti D. The Role of Inflammation in AMD. Presented at the congress Retina in Pro-
gress: Present and Future; June 4-6, 2009; Milan, Italy.
Lanzetta P, Veritti D. Ranibizumab. Presented at the congress Retina in Progress: Present and Futu-
re; June 4-6, 2009; Milan, Italy.
Lanzetta P, Veritti D, Dal Mas G. Nuove Tecniche di Fotocoagulazione Laser. Presented at the con-
gress “Update sulla Retinopatia Diabetica”; February 12, 2010; Milan, Italy.
Veritti D. Desametazone nella Terapia dell’Edema Maculare Diabetico. Presented at the congress
“Retinopatia Diabetica”; March 12, 2010; Reggio Emilia, Italy.
Veritti D. Le Ultime Novità. Presented at the congress “Retinopatia Diabetica”; March 12, 2010;
Reggio Emilia, Italy.
Veritti D, Lanzetta P. Somministrazione di Medicinali nello Spazio Sopracoroideale. Presented at
the congress Retina 2010: Edema Retinico e Coroide; March 27, 2010; Rome, Italy.
Piermarocchi S, Veritti D, Maritan V, Lo Giudice G. Degenerazione Maculare Senile: Uso degli
Anti-VEGF in Ospedale. Presented at the congress Argomenti controversi in Oftalmologia; April 10,
2010; Schio-Thiene, Italy.
Veritti D. Economics. Presented at the congress OCT e Degenerazione Maculare; April 16, 2010;
Milan, Italy.
Veritti D. Un Caso di Edema Maculare. Presented at the congress Macular Advanced Multi-thera-
pies Bologna; April 23, 2010; Bologna, Italy.
Veritti D, Sarao V, Savorgnani C, Polini G, Lanzetta P. Combination Therapy for Chroidal Neova-
scularization Due to Age-Related Macular Degeneration Unresponsive to Anti-VEGF Monotherapy.
Intravitreal Bevacizumab and Triamcinolone Acetonide. Presented at the Association for Research in
Vision and Ophthalmology (ARVO) Annual Meeting; May 2, 2010; Fort Lauderdale, FL, USA.
Zucchiatti I, Savorgnani C, Veritti D, Battaglia Parodi M, Kontadakis DS, Papayannis A, Iacono P,
Lanzetta P, Bandello F. Intravitreal Injection of Bevacizumab for Maculare Edema Secondary to
branch Retinal Vein Occlusion. Presented at the Association for Research in Vision and Ophthalmo-
logy (ARVO) Annual Meeting; May 4, 2010; Fort Lauderdale, FL, USA.
Veritti D. Retinopatia Diabetica. Presented at the congress Degenerazione Maculare Legata all’Età
e Retinopatia Diabetica; May 28, 2010; Udine, Italy.
Veritti D. Terapie Combinate. Presented at the congress Retinopatia Diabetica 2010; June 3, 2010;
Bassano del Grappa, Italy.
Lanzetta P, Veritti D, Dal Mas G. Nuove Prospettive Terapeutiche della Degenerazione Maculare
Legata all’Età di Tipo Secco. Presented at the congress Retina - Presente e Futuro; September 17,
2010; Naples, Italy.
Lanzetta P, Veritti D. Chirurgia 25 gauge del pucker maculare. Presented at the congress What’s
New 2010 Chirurgia Innovativa in Oftalmologia; September 24, 2010; Pordenone, Italy.
Lanzetta P, Veritti D. Il trattamento dell’edema maculare diabetico. Presented at the congress
What’s New 2010 Chirurgia Innovativa in Oftalmologia; September 24, 2010; Pordenone, Italy.
Veritti D. Occhio e micronutrizione. Presented at the congress Occhio, Dieta, Micronutrienti e
Neuroprotezione; November 12, 2010; Udine, Italy.
Lanzetta P, Veritti D. Retinopatia diabetica: nuove terapie e supplementazione. Presented at the
congress Occhio, Dieta, Micronutrienti e Neuroprotezione; November 12, 2010; Udine, Italy.
Lanzetta P, Veritti D. Is there still a role for combination therapy in neovascular AMD?. Presented at
the 10th International AMD and Retina Congress; January 20, 2010; Lugano, Swiss.
Veritti D, Sarao V, Lanzetta P. Esperienza Preliminare con una piattaforma integrata lampada a
fessura, OCT e fotocoagulatore laser. Presented at the Annual Meeting of the “Società Italiana Laser
in Oftalmologia”; January 28, 2011; Cortina d’Ampezzo, Italy.
Lanzetta P, Veritti D. Diabetic macular edema treatment: what the evidence says and future per-
spectives. Presented at the congress “Present and future challenges of severe retinal diseases”; Febru-
ary 4, 2011; Verona, Italy.
Veritti D. Ranibizumab in the treatment of retinal vein occlusion. Presented at the congress “Nuove
prospettive di trattamento nelle malattie occlusive della retina”; February 11, 2011; Reggio Emilia,
Italy.
Lanzetta P, Veritti D. Avastin: what evidence available. Presented at “the 2nd World Congress on
Controversies in Ophthalmology”; March 5, 2011; Barcelona, Spain.
Lanzetta P, Veritti D, Gabai A. 12-month treatment with intravitreal ranibizumab for wet AMD in a
“real world” clinical setting. Presented at “the Macula Society 34rth Annual Meeting”; March 11,
2011; Boca Raton, FL, USA.
Veritti D, Lanzetta P. Nuove terapie per l’atrofia geografica. Presented at the congress “Retina 2011:
Nuove tecnologie, nuove terapie”; March 25, 2011; Rome, Italy.
Veritti D, Lanzetta P. Nuovi sistemi di somministrazione per le patologie retiniche. Presented at the
congress “Retina 2011: Nuove tecnologie, nuove terapie”; March 25, 2011; Rome, Italy.
Veritti D, Toneatto G, Lanzetta P. Twenty-five Gauge Transconjunctival Sutureless Vitrectomy with
Low-concentration Infracyanine Green-assisted Internal Limiting Membrane Peeling in Idiopathic
Macular Pucker: Outcomes and Predictive Factors. Presented at the Association for Research in Vi-
sion and Ophthalmology (ARVO) Annual Meeting; May 4, 2011; Fort Lauderdale, FL, USA.
Sarao V, Veritti D, Lanzetta P. Real-time OCT Scanning During Sub-threshold Laser Irradiation.
Presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting;
May 2, 2011; Fort Lauderdale, FL, USA.
Veritti D, Lanzetta P. Real-time OCT Scanning During Sub-threshold Laser Irradiation. Presented
at the 33rd International Congress of Ophthalmology; May 14, 2011; Trieste, Italy.
Veritti D, Lanzetta P. Il trattamento delll'edema maculare diabetico: il ruolo dei farmaci corticoste-
roidi. Presented at the Congress Retinopatia Diabetica; June 3, 2011; Bassano del Grappa, Italy.
Veritti D, Lanzetta P. Effects of Intravitreal Anti-VEGF Agents on Retinal Morphology, Neovascu-
lar Network Size and Best Corrected Visual Acuity in Patients with Pigment Epithelium Detachment
due to Occult Choroidal Neovascularization. Presented at the Retina Society Annual Meeting; Sep-
tember 3, 2011; Rome, Italy.
Veritti D. Etica e Pubblicazione. Presented at the Course Medical Writing; December 13, 2011;
Padova, Italy.
Veritti D, Gabai A, Lanzetta P. Trabeculoplastica laser selettiva: una review della letteratura. Presen-
ted at the Annual Meeting of the “Società Italiana Laser in Oftalmologia”; January 26, 2012; Cortina
d’Ampezzo, Italy.
Veritti D, Lanzetta P. Nuove terapie della DMLE atrofica. Presented at the congress Retina 2012:
Retina Interna, Cellule Ganglionari e Ultime Terapie; March 31, 2012; Rome, Italy.
Veritti D, Lanzetta P. L’albero decisionale nella neovascolarizzazione da DMLE. Presented at the
congress Retina 2012: Retina Interna, Cellule Ganglionari e Ultime Terapie; March 31, 2012; Ro-
me, Italy.
Sarao V, Veritti D, Lanzetta P. Intravitreal Bevacizumab For Choroidal Neovascularization Due To
Causes Other Than Age-related Macular Degeneration. Presented at the Association for Research in
Vision and Ophthalmology (ARVO) Annual Meeting; May 9, 2012; Fort Lauderdale, FL, USA.
Lanzetta P, Veritti D, Sarao V. Twelve-month Treatment With Intravitreal Bevacizumab For Diabe-
tic Macular Edema In A "Real World" Clinical Setting. Presented at the Association for Research in
Vision and Ophthalmology (ARVO) Annual Meeting; May 6, 2012; Fort Lauderdale, FL, USA.
Veritti D, Santarelli M, Dal Mas G, Lanzetta P. Morphological and Functional Correlations Before
and After 25-gauge Surgery for Idiopathic Macular Pucker. A Spectral Domain OCT and Micrope-
rimetric Study. Presented at the Association for Research in Vision and Ophthalmology (ARVO)
Annual Meeting; May 7, 2012; Fort Lauderdale, FL, USA.
Anterior segment procedures (first) Anterior segment procedures (assistant) Posterior segment procedures (assistant) Pazopanib eye drops in choroidal neovascularization due to AMD (MD7110852). Phase IIb.
Nevanac eye drops following cataract surgery in diabetic retinopathy patients (Mizar - C-09-003) Phase IIIb.
A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebocontrolled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (1% and 2%) Twice Daily for the Treatment of Center-involving Clinically Significant Macular Edema Associated with Diabetic Retinopathy (FOV2304/CLIN/201/P). Phase II.
Long term safety and tolerability of 0.5 mg Fingolimod in patients with relapsing forms of multiple sclerosis. Phase III.
A prospective observational study of ophthalmologic function in patients receiving Linezolid fot two months or greater. Phase III.
A 24-months, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intravi-treal injections in patients with visual impairment due to macular edema secondary to central retinal vein occlusion. Phase IIIb.
PROFESSIONAL-SCIENTIFIC ASSOCIATIONS / PANELSAssociation for Research in Vision and Ophthalmology (ARVO) Società Italiana Laser in Oftalmologia (SILO) NONPROFIT ASSOCIATIONSAssociazione Maculopatie Degenerative Onlus (AMD Onlus)

Source: http://www.iemo.eu/download/documenti/Veritti.pdf